Abbott Laboratories [ABT] stock prices are down -1.24% to $112.23 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABT shares have lost -0.44% over the last week, with a monthly amount drifted -1.90%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on September 19, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $131. Previously, Edward Jones downgraded its rating to Hold on July 30, 2024. On May 30, 2024, Goldman initiated with a Buy rating and assigned a price target of $121 on the stock. Wolfe Research upgraded its rating to a Peer Perform. Morgan Stanley downgraded its rating to a Equal-Weight but $112 remained the price target by the analyst firm on May 30, 2023. Wolfe Research reiterated a Underperform rating for this stock on April 20, 2023, and downed its price target to $103. In a note dated April 20, 2023, UBS reiterated an Buy rating on this stock and boosted its target price from $117 to $130.
The stock price of Abbott Laboratories [ABT] has been fluctuating between $89.67 and $121.64 over the past year. Currently, Wall Street analysts expect the stock to reach $137.85 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $112.23 at the most recent close of the market. An investor can expect a potential return of 22.83% based on the average ABT price forecast.
Analyzing the ABT fundamentals
The Abbott Laboratories [NYSE:ABT] reported sales of 40.73B for trailing twelve months, representing a surge of 4.00%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.14 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 111.51 points at the first support level, and at 110.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 113.23, and for the 2nd resistance point, it is at 114.23.
Ratios To Look Out For
It’s worth pointing out that Abbott Laboratories [NYSE:ABT]’s Current Ratio is 1.68. As well, the Quick Ratio is 1.18, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 4.79, the price to book ratio is 4.97 and price to earnings (TTM) ratio is 35.42.
Transactions by insiders
Recent insider trading involved Ford Robert B, CHAIRMAN AND CEO, that happened on Sep 12 ’24 when 0.14 million shares were sold. Officer, Robert B. Ford completed a deal on Sep 12 ’24 to buy 0.14 million shares. Meanwhile, VICE PRESIDENT MCCOY JOHN A. JR. sold 27.0 shares on Sep 04 ’24.
